BOUCHERVILLE, QC, Oct. 28, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (the "Company" or "LSL Pharma"), an integrated Canadian pharmaceutical company, is pleased to announce that Health Canada has approved its first six (6) sterile ophthalmic solutions for the treatment of glaucoma and allergies. The commercial launch of these products is expected to begin in the second quarter of 2026.
Read more at newswire.caHEALTH CANADA GRANTS LSL PHARMA GROUP APPROVAL TO COMMERCIALIZE SIX NEW STERILE OPHTHALMIC SOLUTIONS
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.